Last 12 months
Inside the activity.
2 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2026 Filed Aug 12, 2026 17:01 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Exercise / conversionRestricted Stock Units · Derivative | 11,519 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-056061 · wk-form4_1786554094.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,519 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments with the third and final vesting occurring on August 11, 2026. F2 · derivative.expiration_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments with the third and final vesting occurring on August 11, 2026. Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 17:01 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Tax withholdingCommon Stock | 4,134 | $13.62 | $56,305.08 |
DisclosureSEC source: 0001628280-26-056061 · wk-form4_1786554094.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,432.477 Read SEC document |
| August 11, 2026 Filed Aug 12, 2026 17:01 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Exercise / conversionCommon Stock | 11,519 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-056061 · wk-form4_1786554094.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,566.477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2026 Filed Aug 5, 2026 20:04 UTC |
Drinane Juliana PapaHead of Mfg & Supply
|
SaleCommon Stock | 14,761 | $13.57 | $200,306.77 |
DisclosureSEC source: 0001628280-26-053306 · wk-form4_1785960273.xml · nonDerivative · entry 1 Drinane Juliana Papa · CIK 0002096406 · Head of Mfg & Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,474.703 Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 20:38 UTC |
Ozuah PhilipDirector
|
GrantPhantom Stock · Derivative | 17,857.143 | $13.44 | $240,000.00 |
DisclosureSEC source: 0001628280-26-043245 · wk-form4_1781555927.xml · derivative · entry 1 Ozuah Philip · CIK 0001859685 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,141.133 Underlying: Common Stock · 17,857.143 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 20:36 UTC |
LAZARUS ROCHELLE BDirector
|
GrantPhantom Stock · Derivative | 17,857.143 | $13.44 | $240,000.00 |
DisclosureSEC source: 0001628280-26-043241 · wk-form4_1781555807.xml · derivative · entry 1 LAZARUS ROCHELLE B · CIK 0001082206 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,141.135 Underlying: Common Stock · 17,857.143 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 20:40 UTC |
Sequeira RamonaDirector
|
GrantPhantom Stock · Derivative | 17,857.143 | $13.44 | $240,000.00 |
DisclosureSEC source: 0001628280-26-043249 · wk-form4_1781556043.xml · derivative · entry 1 Sequeira Ramona · CIK 0001811081 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,950.644 Underlying: Common Stock · 17,857.143 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 20:33 UTC |
Ezekowitz AlanDirector
|
GrantPhantom Stock · Derivative | 17,857.143 | $13.44 | $240,000.00 |
DisclosureSEC source: 0001628280-26-043224 · wk-form4_1781555609.xml · derivative · entry 1 Ezekowitz Alan · CIK 0001780209 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,141.131 Underlying: Common Stock · 17,857.143 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 20:34 UTC |
Gayle Helene DDirector
|
GrantPhantom Stock · Derivative | 17,857.143 | $13.44 | $240,000.00 |
DisclosureSEC source: 0001628280-26-043228 · wk-form4_1781555680.xml · derivative · entry 1 Gayle Helene D · CIK 0001487047 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,141.134 Underlying: Common Stock · 17,857.143 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 20:32 UTC |
ESSNER ROBERTDirector
|
GrantPhantom Stock · Derivative | 17,857.143 | $13.44 | $240,000.00 |
DisclosureSEC source: 0001628280-26-043218 · wk-form4_1781555540.xml · derivative · entry 1 ESSNER ROBERT · CIK 0001187297 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,141.129 Underlying: Common Stock · 17,857.143 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 20:41 UTC |
Sharp ShaliniDirector
|
GrantPhantom Stock · Derivative | 17,857.143 | $13.44 | $240,000.00 |
DisclosureSEC source: 0001628280-26-043256 · wk-form4_1781556099.xml · derivative · entry 1 Sharp Shalini · CIK 0001377202 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,495.885 Underlying: Common Stock · 17,857.143 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 20:39 UTC |
Patton Cynthia MDirector
|
GrantPhantom Stock · Derivative | 17,857.143 | $13.44 | $240,000.00 |
DisclosureSEC source: 0001628280-26-043247 · wk-form4_1781555983.xml · derivative · entry 1 Patton Cynthia M · CIK 0001560565 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,141.129 Underlying: Common Stock · 17,857.143 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 20:37 UTC |
Leone Deborah RDirector
|
GrantPhantom Stock · Derivative | 17,857.143 | $13.44 | $240,000.00 |
DisclosureSEC source: 0001628280-26-043243 · wk-form4_1781555861.xml · derivative · entry 1 Leone Deborah R · CIK 0001859703 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,141.135 Underlying: Common Stock · 17,857.143 shares Expires not disclosed F1 · derivative.exercise_price: Each phantom stock unit is an economic equivalent of one share of Organon & Co. ("Organon") common stock, or 1-for-1. F2 · derivative.exercise_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F2 · derivative.expiration_date: Phantom stock units are granted under the Organon Non-Employee Director Savings Plan (the "Plan") and are payable in cash upon settlement after the reporting person's termination of service as a director pursuant to the terms of the Plan. F3 · balance_after: Holdings include phantom stock acquired in dividend reinvestment transactions on September 11, 2025, December 11, 2025, March 12, 2026 and June 11, 2026. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:00 UTC Amendment |
Holzbaur LynetteSVP and Corporate Controller
|
SaleCommon Stock | 26,448.366 | $13.35 | $353,080.40 |
DisclosureSEC source: 0001628280-26-032059 · wk-form4a_1778184038.xml · nonDerivative · entry 2 Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · balance_after: This amendment updates the reporting of the 26,448.366 shares in Table I to reflect a sale (disposition) instead of a purchase. Read SEC document |
| May 06, 2026 Filed May 7, 2026 20:00 UTC Amendment |
Holzbaur LynetteSVP and Corporate Controller
|
OtherCommon Stock | 45.939 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-032059 · wk-form4a_1778184038.xml · nonDerivative · entry 1 Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,448.366 F1 · balance_after: This reflects the acquisition of 45.939 shares of common stock not previously required to be reported. Read SEC document |
| May 06, 2026 Filed May 7, 2026 14:02 UTC |
Holzbaur LynetteSVP and Corporate Controller
|
PurchaseCommon Stock | 26,448.366 | $13.35 | $353,080.40 |
DisclosureSEC source: 0001628280-26-031780 · wk-form4_1778162547.xml · nonDerivative · entry 1 Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,850.793 Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:26 UTC |
Drinane Juliana PapaInterim Head of Mfg & Supply
|
Exercise / conversionRestricted Stock Units · Derivative | 10,073 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023209 · wk-form4_1775161569.xml · derivative · entry 7 Drinane Juliana Papa · CIK 0002096406 · Interim Head of Mfg & Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,148 Underlying: Common Stock · 10,073 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F5 · derivative.exercise_date: On March 31, 2025, the Reporting Person was granted 30,221 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. F5 · derivative.expiration_date: On March 31, 2025, the Reporting Person was granted 30,221 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:26 UTC |
Drinane Juliana PapaInterim Head of Mfg & Supply
|
Exercise / conversionRestricted Stock Units · Derivative | 6,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023209 · wk-form4_1775161569.xml · derivative · entry 6 Drinane Juliana Papa · CIK 0002096406 · Interim Head of Mfg & Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,378 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F4 · derivative.exercise_date: On March 31, 2023, the Reporting Person was granted 19,132 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. F4 · derivative.expiration_date: On March 31, 2023, the Reporting Person was granted 19,132 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:26 UTC |
Drinane Juliana PapaInterim Head of Mfg & Supply
|
GrantRestricted Stock Units · Derivative | 125,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023209 · wk-form4_1775161569.xml · derivative · entry 5 Drinane Juliana Papa · CIK 0002096406 · Interim Head of Mfg & Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,208 Underlying: Common Stock · 125,208 shares Expires not disclosed F2 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 125,208 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 125,208 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 125,208 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:26 UTC |
Drinane Juliana PapaInterim Head of Mfg & Supply
|
Tax withholdingCommon Stock | 3,451 | $5.70 | $19,670.70 |
DisclosureSEC source: 0001628280-26-023209 · wk-form4_1775161569.xml · nonDerivative · entry 4 Drinane Juliana Papa · CIK 0002096406 · Interim Head of Mfg & Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,235.703 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:26 UTC |
Drinane Juliana PapaInterim Head of Mfg & Supply
|
Exercise / conversionCommon Stock | 10,073 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023209 · wk-form4_1775161569.xml · nonDerivative · entry 3 Drinane Juliana Papa · CIK 0002096406 · Interim Head of Mfg & Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,686.703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:26 UTC |
Drinane Juliana PapaInterim Head of Mfg & Supply
|
Tax withholdingCommon Stock | 2,185 | $5.70 | $12,454.50 |
DisclosureSEC source: 0001628280-26-023209 · wk-form4_1775161569.xml · nonDerivative · entry 2 Drinane Juliana Papa · CIK 0002096406 · Interim Head of Mfg & Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,613.703 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:26 UTC |
Drinane Juliana PapaInterim Head of Mfg & Supply
|
Exercise / conversionCommon Stock | 6,378 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023209 · wk-form4_1775161569.xml · nonDerivative · entry 1 Drinane Juliana Papa · CIK 0002096406 · Interim Head of Mfg & Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,798.703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:06 UTC |
Holzbaur LynetteSVP and Corporate Controller
|
Exercise / conversionRestricted Stock Units · Derivative | 6,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023139 · wk-form4_1775160371.xml · derivative · entry 8 Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,715 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F6 · derivative.exercise_date: On March 31, 2025, the Reporting Person was granted 20,147 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. F6 · derivative.expiration_date: On March 31, 2025, the Reporting Person was granted 20,147 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:06 UTC |
Holzbaur LynetteSVP and Corporate Controller
|
Exercise / conversionRestricted Stock Units · Derivative | 4,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023139 · wk-form4_1775160371.xml · derivative · entry 7 Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,252 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F5 · derivative.exercise_date: On March 31, 2023, the Reporting Person was granted 12,755 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. F5 · derivative.expiration_date: On March 31, 2023, the Reporting Person was granted 12,755 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:06 UTC |
Holzbaur LynetteSVP and Corporate Controller
|
GrantRestricted Stock Units · Derivative | 41,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023139 · wk-form4_1775160371.xml · derivative · entry 6 Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,736 Underlying: Common Stock · 41,736 shares Expires not disclosed F3 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 41,736 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F3 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 41,736 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F3 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 41,736 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:06 UTC |
Holzbaur LynetteSVP and Corporate Controller
|
GrantRestricted Stock Units · Derivative | 75,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023139 · wk-form4_1775160371.xml · derivative · entry 5 Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,125 Underlying: Common Stock · 75,125 shares Expires not disclosed F2 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 75,125 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 75,125 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 75,125 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:06 UTC |
Holzbaur LynetteSVP and Corporate Controller
|
Tax withholdingCommon Stock | 1,914 | $5.70 | $10,909.80 |
DisclosureSEC source: 0001628280-26-023139 · wk-form4_1775160371.xml · nonDerivative · entry 4 Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,402.427 F1 · price: The price is the closing market price for Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:06 UTC |
Holzbaur LynetteSVP and Corporate Controller
|
Exercise / conversionCommon Stock | 6,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023139 · wk-form4_1775160371.xml · nonDerivative · entry 3 Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,316.427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:06 UTC |
Holzbaur LynetteSVP and Corporate Controller
|
Tax withholdingCommon Stock | 1,212 | $5.70 | $6,908.40 |
DisclosureSEC source: 0001628280-26-023139 · wk-form4_1775160371.xml · nonDerivative · entry 2 Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,601.427 F1 · price: The price is the closing market price for Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:06 UTC |
Holzbaur LynetteSVP and Corporate Controller
|
Exercise / conversionCommon Stock | 4,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023139 · wk-form4_1775160371.xml · nonDerivative · entry 1 Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,813.427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:09 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Exercise / conversionRestricted Stock Units · Derivative | 12,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023146 · wk-form4_1775160581.xml · derivative · entry 7 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,625 Underlying: Common Stock · 12,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F5 · derivative.exercise_date: On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. F5 · derivative.expiration_date: On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:09 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Exercise / conversionRestricted Stock Units · Derivative | 6,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023146 · wk-form4_1775160581.xml · derivative · entry 6 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,201 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F4 · derivative.exercise_date: On March 31, 2023, the Reporting Person was granted 18,600 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. F4 · derivative.expiration_date: On March 31, 2023, the Reporting Person was granted 18,600 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:09 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
GrantRestricted Stock Units · Derivative | 183,639 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023146 · wk-form4_1775160581.xml · derivative · entry 5 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,639 Underlying: Common Stock · 183,639 shares Expires not disclosed F2 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:09 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Tax withholdingCommon Stock | 3,508 | $5.70 | $19,995.60 |
DisclosureSEC source: 0001628280-26-023146 · wk-form4_1775160581.xml · nonDerivative · entry 4 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,639.163 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were granted. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:09 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Exercise / conversionCommon Stock | 12,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023146 · wk-form4_1775160581.xml · nonDerivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,147.163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:09 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Tax withholdingCommon Stock | 1,767 | $5.70 | $10,071.90 |
DisclosureSEC source: 0001628280-26-023146 · wk-form4_1775160581.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,835.163 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were granted. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:09 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Exercise / conversionCommon Stock | 6,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023146 · wk-form4_1775160581.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,602.163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:18 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Exercise / conversionRestricted Stock Units · Derivative | 13,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023188 · wk-form4_1775161114.xml · derivative · entry 4 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,864 Underlying: Common Stock · 13,431 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F4 · derivative.exercise_date: On March 31, 2025, the Reporting Person was granted 40,295 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. F4 · derivative.expiration_date: On March 31, 2025, the Reporting Person was granted 40,295 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:18 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
GrantRestricted Stock Units · Derivative | 200,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023188 · wk-form4_1775161114.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,333 Underlying: Common Stock · 200,333 shares Expires not disclosed F2 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 200,333 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 200,333 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 200,333 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:18 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Tax withholdingCommon Stock | 4,820 | $5.70 | $27,474.00 |
DisclosureSEC source: 0001628280-26-023188 · wk-form4_1775161114.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,047.477 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:18 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Exercise / conversionCommon Stock | 13,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023188 · wk-form4_1775161114.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,867.477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:13 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 21,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023157 · wk-form4_1775160787.xml · derivative · entry 8 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,094 Underlying: Common Stock · 21,546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F6 · derivative.exercise_date: On March 31, 2025, the Reporting Person was granted 64,640 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. F6 · derivative.expiration_date: On March 31, 2025, the Reporting Person was granted 64,640 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:13 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 12,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023157 · wk-form4_1775160787.xml · derivative · entry 7 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,047 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F5 · derivative.exercise_date: On March 31, 2023, the Reporting Person was granted 36,139 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. F5 · derivative.expiration_date: On March 31, 2023, the Reporting Person was granted 36,139 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:13 UTC |
WALSH MATTHEW MChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 83,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023157 · wk-form4_1775160787.xml · derivative · entry 6 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,472 Underlying: Common Stock · 83,472 shares Expires not disclosed F3 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 83,472 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F3 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 83,472 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F3 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 83,472 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:13 UTC |
WALSH MATTHEW MChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 321,368 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023157 · wk-form4_1775160787.xml · derivative · entry 5 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,368 Underlying: Common Stock · 321,368 shares Expires not disclosed F2 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 321,368 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 321,368 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 321,368 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:13 UTC |
WALSH MATTHEW MChief Financial Officer
|
Tax withholdingCommon Stock | 7,380 | $5.70 | $42,066.00 |
DisclosureSEC source: 0001628280-26-023157 · wk-form4_1775160787.xml · nonDerivative · entry 4 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,746 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:13 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionCommon Stock | 21,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023157 · wk-form4_1775160787.xml · nonDerivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:13 UTC |
WALSH MATTHEW MChief Financial Officer
|
Tax withholdingCommon Stock | 4,127 | $5.70 | $23,523.90 |
DisclosureSEC source: 0001628280-26-023157 · wk-form4_1775160787.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,580 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:13 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionCommon Stock | 12,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023157 · wk-form4_1775160787.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.